Navigation Links
St. Jude announces breakthrough in eye cancer treatment

cals (Nutley, N.J.) for a similar use against a related target called MDM2 in adult cancer cells. The success in knocking out MDMX with nutlin-3 represents the first example of local delivery of a targeted chemotherapy drug for any childhood cancer, Dyer said.

Targeted therapy uses a customized drug to disable a specific molecule inside a growing cancer cell; local delivery is the placement of a drug at the site of disease, rather than systemic treatment. In systemic treatment, such as chemotherapy, a drug is infused into the body through a vein and then circulates, often causing toxic side effects that are especially challenging in children.

After demonstrating that nutlin-3 is effective when applied directly to the eye, the St. Jude team modified the treatment by combining this molecule with topotecan, a drug also being investigated in the treatment of retinoblastoma. Local delivery of this two-drug targeted treatment was even more effective, reducing tumor size significantly more than the most effective known combination of standard chemotherapy drugs.

"The findings suggest that this treatment not only could offer children with retinoblastoma more effective and less-toxic treatment," Dyer said. "It could also increase the chance that their vision can be preserved by eliminating the tumor and preventing its spread from the eye to the rest of the body."

The discovery that blocking MDMX releases the apoptosis response in retinoblastoma has important implications for certain forms of adult cancers as well. "Some forms of breast, lung, prostate and colon cancer are caused by abnormally large quantities of MDMX in the cells," Dyer explained. "So knocking out MDMX in those cancers might also dramatically reduce tumor size. And administering the drug directly to the site of the tumor could make the treatment especially effective while avoiding the toxicity caused by systemic exposure." This could mean the eventual elimination of all-
'"/>

Source:St. Jude Children's Research Hospital


Page: 1 2 3 4

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
4. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
5. GlycoFi announces the first production of antibodies with human glycosylation in yeast
6. NHGRI announces new sequencing targets
7. CHAVI announces international search for genes affecting HIV response
8. NHGRI announces latest sequencing targets
9. MUHC announces a transplant first in Quebec
10. NIH announces phase III clinical trial of creatine for Parkinsons disease
11. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Jude announces breakthrough eye cancer treatment

(Date:9/17/2014)... professor and his doctoral student have designed a device ... collected from fog and dew., The device could provide ... around the globe., Cheng Luo, professor in the Mechanical ... in the same College of Engineering department, published "Bioinspired ... ACS, (American Chemical Society) Applied Materials & ...
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... UTSouthwestern Medical Center have found that the most common ... helps repair the lining of blood vessels. Individuals with ... of this repair, putting them at higher risk for ... one mechanism by which apoE3 promotes a healthy cardiovascular ... said Dr. Philip Shaul , Professor of Pediatrics ...
Breaking Biology News(10 mins):Shorebird's beak inspires UT Arlington research on water collection 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Protein variant may boost cardiovascular risk by hindering blood vessel repair 2
... codes of over 40,000 women -- including those ... disease – has uncovered five common genetic variants that ... a paper published online today in the journal Nature, ... association study report that these five genes code for ...
... of the Health Sciences (USU) suggests that it may ... the myriad strains of the HIV virus. HIV is ... stimulate the body to produce cross-reactive antibodies that will ... of truly broad-spectrum neutralizing antibodies may be an achievable ...
... disease typically characterized by the slow but progressive onset ... about five years after diagnosis. However, according to a ... PLoS ONE, a subset of patients with a specific ... complete pulmonary failure and death without a lung transplant. ...
Cached Biology News:First confirmed common genetic risk factors for breast cancer 2Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients 2
(Date:9/17/2014)... Rockville, MD (PRWEB) September 17, 2014 ... Small Business Innovation Research (SBIR) grant to support the ... award will provide ITI with approximately $255,000 over one ... a leading cause of food allergy, affect over one ... anaphylaxis behind peanut allergy. Tree nut exposure is also ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... slogans and catchy buzz-phrases to capture the media spotlight as ... equals broadband connectivity (EDEBC) is one of those slogans. ... the test of time. Otherwise, it fades faster than the ... EDEBC is becoming very proven because future economic viability is ...
... advice and $25,000 in cash prizes will be at ... 2007 Northeast Wisconsin Business Plan Contest . , ... existing businesses that are changing direction, in northeastern Wisconsin. ... place reward, entrepreneurs will receive advice about crafting their ...
... - An early-stage company developing diagnostics to test for kidney ... investments to secure federal clearance for its first clinical product. ... of $3.2 million since its inception in 1999, will use ... research and development activities. ,The round was led by Appleton-based ...
Cached Biology Technology:Locations must have connectivity to be viable 2Locations must have connectivity to be viable 3Locations must have connectivity to be viable 4Renovar captures $1.2M for product development 2
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
Biology Products: